Clinicaltrials.gov identifier:
NCT04267939 (https://clinicaltrials.gov/show/NCT04267939)
Treatment
Advanced ovarian cancer or other solid tumors
Study Contact Information:
For additional information, contact: Bayer Clinical Trials by phone: 1-888-842-2937 or by email
This study will look at how well how people with advanced ovarian, fallopian tube or primary peritoneal cancer or other solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib. This study is open to participants who have had their ovarian cancer progress while on a PARP inhibitor.
This is an open-label, single group study. All participants will receive the same medications.
Study participants will be placed into one of three groups based on their situation.
All study participants will receive the following:
Study participants will be followed for up to 24 months.
Massachusetts
Boston, MA
Dana-Farber Cancer Institute
New York
New York, NY
Memorial Sloan-Kettering Cancer Center
Ohio
Cleveland
Cleveland Clinic
Texas
Houston
MD Anderson Cancer Center
People age 18 years and older can be considered for enrollment in this study if they:
People cannot participate if they have any of the following:
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.